<DOC>
	<DOCNO>NCT00002588</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness topotecan etoposide treat patient recurrent refractory leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Recurrent Refractory Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose topotecan combine etoposide patient relapse refractory acute myelogenous leukemia , acute lymphoblastic leukemia , blastic phase chronic myelogenous leukemia . II . Determine toxicity regimen patient . III . Measure serum level topotecan steady state correlate change topoisomerase II content leukemic blast . IV . Assess whether feasible correlate upregulation topoisomerase II expression tumor response etoposide subsequent Phase II study . V. Assess whether level pretreatment expression topoisomerases I II leukemic cell predictive clinical response . VI . Assess whether feasible develop pharmacodynamic assay base posttreatment apoptotic change leukemic blast whether could correlate tumor response subsequent phase II trial . VII . Determine response patient treat regimen . OUTLINE : Induction : 2-Drug Combination Chemotherapy . Topotecan , TOPO , NSC-609699 ; Etoposide , VP-16 , NSC-141540 . Consolidation : 2-Drug Combination Chemotherapy . TOPO ; VP-16 . PROJECTED ACCRUAL : 15-23 patient accrue approximately 18 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myelogenous leukemia ( M0M7 ) acute lymphoblastic leukemia ( L1L2 ) Refractory first subsequent relapse Circulating blast present OR Greater 5 % blast bone marrow Acute myelogenous leukemia secondary myelodysplastic syndrome cytotoxic therapy Untreated OR Maximum 2 intensive induction regimens Chronic myelogenous leukemia blastic lymphoid crisis Untreated OR Maximum 2 intensive induction regimens No CNS leukemia PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 03 Life expectancy : At least 4 week Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL AST ALT less 3 time normal Alkaline phosphatase less 3 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No myocardial infarction within 6 month No active ischemic cardiac disease No poorly control congestive heart failure No symptomatic cardiac disease Left ventricular ejection fraction least 40 % Pulmonary : No symptomatic restrictive obstructive lung disease Other : No severe neurologic disease No active infection unless stable antimicrobial therapy fever tumor relate HIV negative Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : At least 2 week since prior cytotoxic therapy ( except hydroxyurea steroid ) Biologic therapy : No prior bone marrow transplantation At least 3 day since prior hematopoietic growth factor Chemotherapy : No prior topotecan camptothecin analogue Prior etoposide allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>